Company-sponsored research includes five poster presentations, one of which was awarded a poster of distinction, and an oral presentation highlighting advances in Wilson disease monitoring, treatment experience, and clinical trial innovation
CHICAGO, Ill., November 2, 2026 – Orphalan Inc., the US affiliate of a global pharmaceutical company dedicated to improving the lives of people living with rare diseases, today announced its participation in The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.
At this year’s meeting, Orphalan-sponsored research will be featured in five poster presentations and one oral presentation focused on Wilson disease. Research topics include approaches to disease monitoring, treatment adherence, patient experience, and an investigational once-daily trientine tetrahydrochloride formulation.
“We are pleased to share new scientific findings that reflect our ongoing commitment to advancing the understanding and management of Wilson disease,” said Jamie Heise, Senior Director, U.S. Medical Affairs, Orphalan. “Through collaboration with researchers and healthcare professionals, we continue to generate meaningful evidence to better understand disease monitoring, inform clinical practice, and address unmet needs in the Wilson disease community.”
Scientific Presentations
Poster Presentations
Thursday, November 5, 2026 | 12:00 PM-1:00 PM
- Poster 1419: Poster of Distinction, Can a Novel Instant Release Trientine Tetrahydrochloride Formulation Be Effective When Administered Once-Daily? Results of the TRIUMPH-3 Pharmacokinetic Study,
Presenter: Michael Schilsky, MD, FAASLD - Poster 1425: Real World Evidence of Therapy Impact of Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool in Newly Diagnosed Wilson Disease
Presenter: Michael Schilsky, MD, FAASLD - Poster 1428: Virtual CME Simulation Improves Multi-Specialty Performance in the Diagnosis and Management of Wilson Disease
Presenter: Jovana Lubarda, PhD - Poster 1430: Understanding the Drivers of Treatment Experience and Adherence in Wilson Disease– What Do Patient Interviews and Reported Outcomes from a Phase 2 Study Evaluating a New Trientine Tetrahydrochloride Formulation Tell Us?
Presenter: Emmanuel Tsochatzis MD, PhD, MSc, FEBTM, FRCP - Poster 1434: De-centralized Clinical Trials in Rare Disease; Incorporating the Patient Voice in the Evaluation of Tolerability, Treatment Satisfaction and Adherence of a Novel Trientine Tetrahydrochloride Formulation for the Treatment of Wilson Disease
Presenter: Emmanuel Tsochatzis MD, PhD, MSc, FEBTM, FRCP
Oral Presentation
Sunday, November 8, 2026 | 11:45 AM-12:00 PM
- Real World Evidence of Therapy Impact in Unstable Wilson Disease Using Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool - Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
Presenter: Michael Schilsky, MD, FAASLD
Industry Theater Presentation
In addition to the scientific presentations, Orphalan will host an industry theater session.
Peer to Peer Series on Wilson Disease: Unmet Needs in Wilson Disease, Strategies for Long-Term Management, and the Role of an Approved Treatment Option
Date: November 8, 2026
Time: 1:30 PM-2:00 PM
Location: TLM Theater #2, Exhibit Hall F, Colorado Convention Center
Speaker: Robert G. Gish, MD, FAASLD
This promotional presentation will explore ongoing unmet needs in Wilson disease, discuss strategies for long-term disease management, and review the role of an approved treatment option.
Visit Orphalan at Booth #1173
Conference attendees are invited to visit Booth #1173 to learn more about Orphalan’s commitment to the Wilson disease community and its ongoing efforts to advance research, education, and patient-focused care.
About Wilson Disease
Wilson disease is a rare inherited disorder of copper metabolism caused by mutations in the ATP7B gene. The disease prevents the body from eliminating excess copper, leading to toxic accumulation in tissues and organs, primarily the liver and brain. Without lifelong treatment, Wilson disease can give rise to serious hepatic, neurologic, and psychiatric complications, and importantly, untreated Wilson disease can be fatal.
About Orphalan
Orphalan is a pharmaceutical company dedicated to developing and commercializing treatments for rare diseases, including Wilson disease. The company’s portfolio has recently expanded to include infantile epileptic spasms syndrome (IESS), a rare form of pediatric epilepsy, as well as neuro-oncology, focusing on conditions with significant unmet medical need. By combining scientific rigor with a strong patient-centered mindset, Orphalan works closely with healthcare professionals and patient communities to improve standards of care. Its model emphasizes deep medical engagement, long-term partnerships, and sustainable access to therapies, ensuring that people living with rare and often overlooked disorders receive tailored, specialized treatment options. Find out more at www.orphalan.com
Media Contact
Eleni Fistikaki eleni.fistikaki@orphalan.com M: +44 (0) 7741081694
US-ORPH-CORP-26048
'/%3E%3C/svg%3E){kind=small}